Hematologic malignancies following immune checkpoint inhibition for solid tumors

Mick J.M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S.R. van Lindert, Britt B.M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P.M. Suijkerbuijk

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

3 Citaten (Scopus)

Samenvatting

Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.

Originele taal-2Engels
Pagina's (van-tot)249-255
Aantal pagina's7
TijdschriftCancer Immunology, Immunotherapy
Volume72
Nummer van het tijdschrift1
DOI's
StatusGepubliceerd - 13 jun. 2022

Vingerafdruk

Duik in de onderzoeksthema's van 'Hematologic malignancies following immune checkpoint inhibition for solid tumors'. Samen vormen ze een unieke vingerafdruk.

Citeer dit